HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 473-480

  Kim, Jin A H ^a   Kim, Dong Hwan ^a   Hossain, Mohammad Akbar ^a,b   Kim, Min Young ^a   Sung, Bokyung ^a   Yoon, Jeong Hyun ^a   Suh, Hongsuk ^a   Jeong, Tae Cheon ^c   Chung, Hae Young ^a   Kim, Nam Deuk ^a  

^a Pusan National University   (South Korea)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

^c Yeungnam University   (South Korea)

Author keywords

Apoptosis; Breast cancer cells; Cell cycle; Resveratrol analogue

Indexed keywords

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; NAPHTHOLS; RESORCINOLS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84894474464     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2207     Document Type: Article

References (27)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418, 2011.
3. Kim HJ, Yang KM, Park YS, et al: The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells. Int J Oncol 41: 1628-1634, 2012.
4. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006. (Pubitemid 44136961)
5. Marques FZ, Markus MA and Morris BJ: Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41: 2125-2128, 2009.
6. Khan N, Afaq F and Mukhtar H: Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510, 2008.
7. Fulda S and Debatin KM: Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 41: 786-798, 2005. (Pubitemid 40342561)
8. Garvin S, Ollinger K and Dabrosin C: Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231: 113-122, 2006. (Pubitemid 41779459)
9. Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997. (Pubitemid 127696281)
10. Cai YJ, Wei QY, Fang JG, et al: The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced anti-oxidant and apoptotic activities. Anticancer Res 24: 999-1002, 2004.
11. Jeong SH, Lee JS, Jeong NY, et al: A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol 35: 1353-1360, 2009.
12. + regulatory T cells in FM3A tumor bearing mice. Int Immunopharmacol 14: 328-333, 2012.
13. Jeong NY, Yoon YG, Rho JH, et al: The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int J Oncol 38: 1597-1604, 2011.
14. Jeong SH, Song IS, Kim HK, et al: An analogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 cells via inhibition of mitochondrial biogenesis gene expression. Mol Cells 34: 357-365, 2012.
15. Kim DH, Hossain MA, Kim MY, et al: A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1alpha and VEGF expression, and migration in human prostate cancer cells. Int J Oncol 43: 1915-1924, 2013.
16. Ma Z, Molavi O, Haddadi A, Lai R, Gossage RA and Lavasanifar A: Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol 63: 27-35, 2008.
17. Kotha A, Sekharam M, Cilenti L, et al: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5: 621-629, 2006.
18. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
19. Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27, 1997. (Pubitemid 28037193)
20. Makin G and Dive C: Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer Res 3: 150-153, 2001. (Pubitemid 32390215)
21. Wilkinson MG and Millar JB: Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J 14: 2147-2157, 2000.
22. Bates S, Bonetta L, MacAllan D, et al: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9: 71-79, 1994. (Pubitemid 24020935)
23. Ellis M, Chew YP, Fallis L, et al: Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J 18: 644-653, 1999. (Pubitemid 29057249)
24. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815, 2001. (Pubitemid 32458690)
25. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R and Weissberg P: Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282: 290-293, 1998. (Pubitemid 28487200)
26. Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383-424, 1999. (Pubitemid 29449198)
27. Filomeni G, Graziani I, Rotilio G and Ciriolo MR: trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr 2: 295-305, 2007.